PharmacoEconomics

, Volume 26, Issue 11, pp 911–924 | Cite as

The Impact of Influenza on Working Days Lost

A Review of the Literature
Review Article

Abstract

Seasonal influenza is a prevalent and highly contagious acute respiratory disease that, year on year, results in increased morbidity and mortality on a global scale. Because of the widespread and debilitating nature of the disease, annual influenza epidemics result in substantial workplace absenteeism, and the associated cost of lost productivity is a significant component of the substantial financial burden of the disease to society. The objective of this review was to identify studies that had attempted to quantify the impact of influenza upon otherwise healthy adults in terms of working days lost associated with an episode of influenza.

Studies were included if they reported estimates of working days lost due to clinical, physician and/or self-diagnosis in adult patients or their dependants, or where this figure could be estimated from the data. Searches were conducted in MEDLINE, EMBASE, BIOSIS and the Cochrane Collaboration for articles published since 1995 in English, French or German. Of the 289 papers identified in the search, 28 (9.7%) met the inclusion criteria. The studies, involving study sites in North America, Western Europe, Asia and Australia, were categorized into three groups: (i) those reporting influenza diagnoses confirmed by laboratory testing, i.e. studies where influenza was the unambiguous cause of the working days lost (n = 7 studies reported in ten publications); (ii) those where influenza was confirmed by a physician without an accompanying laboratory test (n = 4 studies); and (iii) those where influenza was self-reported by study participants (n = 14 studies). Qualitative reporting of results was performed because of the large degree of heterogeneity observed between studies, potentially complicating the interpretation of any meta-analysis.

The results from studies involving a laboratory-confirmed influenza diagnosis suggested that the mean number of working days lost ranged between 1.5 and 4.9 days per episode. Those papers that detailed working days lost per episode following physician diagnosis of influenza reported a range of 3.7–5.9 days per episode. Finally, estimates from papers reporting working days lost per episode of self-reported influenza ranged from <1 day to 4.3 days per episode.

Influenza imposes a significant burden on society, and this review highlights the significant economic impact it causes, i.e. the loss of productivity caused by both absenteeism and by staff functioning at reduced capacity even after they have returned to work. A number of prophylaxis and treatment options exist for influenza and should be given serious consideration in an attempt to reduce the economic burden on society.

Notes

Acknowledgements

We thank Richard Glover, from Wolters Kluwer Health, who provided medical writing support on behalf of F. Hoffmann-La Roche Ltd. Paul Beardsworth is an employee of F. Hoffmann-La Roche Ltd and as such is eligible to receive stock options. Iain Tatt from F. Hoffmann-La Roche Ltd provided statistical advice. No funding was provided to Pharmakos Ltd.

References

  1. 1.
    Couch RB. Influenza: prospects for control. Ann Int Med 2000; 133 (12): 992–8PubMedGoogle Scholar
  2. 2.
    Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian J Immunol 2004; 59 (1): 1–15CrossRefGoogle Scholar
  3. 3.
    Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004; 64 (18): 2031–46PubMedCrossRefGoogle Scholar
  4. 4.
    Nguyen-Van-Tam J. Epidemiology of influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1998: 181–206Google Scholar
  5. 5.
    CDC. Key facts about influenza and the influenza vaccine[online]. Available from URL: http:www.cdc.gov/flu/keyfacts.htm [Accessed 2008 Aug 1]
  6. 6.
    Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7 (35): 1–170Google Scholar
  7. 7.
    EISS. FAQ Influenza[online]. Available from URL: http://www.eiss.org/html/faq_influenza.html [Accessed 2008 Aug 1]
  8. 8.
    World Health Organisation. Factsheet Number 211, revised 2003 Mar[online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs211/en/index.html [Accessed 2008 Aug 1]
  9. 9.
    Molinari NAM, Ortega-Sanchez IR, Messonnier ML. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25 (27): 5086–96PubMedCrossRefGoogle Scholar
  10. 10.
    Lynd LD, Goeree R, O’Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. Pharmacoeconomics 2005; 23 (11): 1083–106PubMedCrossRefGoogle Scholar
  11. 11.
    Anonymous. Economic and social impact of epidemic and pandemic influenza. Vaccine 2006; 24 (44–46): 6776–8CrossRefGoogle Scholar
  12. 12.
    Anonymous. Easing the burden: the challenge of managing influenza. Am J Manag Care 2000; 6 (5 Suppl.): S276–81Google Scholar
  13. 13.
    Sessa A, Lucioni C, D’Ambrosio G, et al. Economic evaluation of clinical influenza in Italy. Int J Med 2005; 7 (1): 14–20Google Scholar
  14. 14.
    Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999; 44: 11–5PubMedCrossRefGoogle Scholar
  15. 15.
    Williams JP, Lednar W. New developments in influenza vaccine technology: a potential new prevention strategy for employers and managed care organizations. AM J Manag Care 2002; 8 (5 Suppl.): S145–56Google Scholar
  16. 16.
    Meier C, Napalkov P, Wegmüller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834–42PubMedCrossRefGoogle Scholar
  17. 17.
    Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283 (8): 1016–24PubMedCrossRefGoogle Scholar
  18. 18.
    Rhoton-Vlasak A. Viral influenza in women. Primary Care Update Ob Gyns 1999; 6 (1): 1–7CrossRefGoogle Scholar
  19. 19.
    Anonymous. Evidence points to influenza vaccination being cost-saving in healthy working adults. Drugs Ther Perspect 2003; 19 (3): 22–5CrossRefGoogle Scholar
  20. 20.
    Anonymous. Zanamivir for influenza. Drug Ther Bull 1999; 37 (11): 81–4Google Scholar
  21. 21.
    Fleming DM. The management of influenza in people of working age. Occup Med 2002; 52 (5): 259–63CrossRefGoogle Scholar
  22. 22.
    Poland GA, Rottinghaus ST, Jacobson RM. Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 2001; 19 (17–19): 2216–20PubMedCrossRefGoogle Scholar
  23. 23.
    Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 1998; 10 (199): 1–428Google Scholar
  24. 24.
    O’Reilly FW, Stevens AB. Sickness absence due to influenza. Occup Med 2002; 52 (5): 265–9CrossRefGoogle Scholar
  25. 25.
    Smith A. The socioeconomic aspects and behavioural effect of influenza. In: Wood C, editor. Influenza: strategies for prevention. London: Royal Society Medicine, 1988: 46–52Google Scholar
  26. 26.
    Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 1994; 10 (193 Pt 1): 1–260Google Scholar
  27. 27.
    Principi N, Esposito S. Are we ready for universal influenza vaccination in paediatrics? Lancet Infect Dis 2004; 4 (2): 75–83PubMedCrossRefGoogle Scholar
  28. 28.
    Teo SS, Nguyen-Van-Tam JS, Booy R. Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps? Arch Dis Child 2005; 90 (5): 532–6PubMedCrossRefGoogle Scholar
  29. 29.
    Block SL. Role of influenza vaccine for healthy children in the US. Paediatr Drugs 2004; 6 (4): 199–209PubMedCrossRefGoogle Scholar
  30. 30.
    Committee on Infectious Diseases. American Academy of Pediatrics. Reduction of the influenza burden in children. Pediatrics 2002; 110 (6): 1246–52CrossRefGoogle Scholar
  31. 31.
    Heikkinen T, Booy R, Campins M, et al. Should healthy children be vaccinated against influenza? Eur J Pediatr 2006; 165 (4): 223–8PubMedCrossRefGoogle Scholar
  32. 32.
    Jacobson RM, Poland GA. Universal vaccination of healthy children against influenza: a role for the cold-adapted intranasal influenza vaccine. Paediatr Drugs 2002; 4 (1): 65–71PubMedGoogle Scholar
  33. 33.
    Gaglani MJ, Herschler GB. Every nose counts: a new influenza vaccine for all healthy schoolchildren? Clin Pediatr 2004; 43 (1): 35–41CrossRefGoogle Scholar
  34. 34.
    Maltezou HC, Drancourt M. Nosocomial influenza in children. J Hosp Infect 2003; 55 (2): 83–91PubMedCrossRefGoogle Scholar
  35. 35.
    Szucs TD. Influenza: the role of burden-of-illness research. Pharmacoeconomics 1999; 16 Suppl. 1: 27–32PubMedCrossRefGoogle Scholar
  36. 36.
    Nichol KA, Lind A, Margolis K, et al. The effectiveness of vaccination in healthy, working adults. N Engl J Med 1995; 333 (14): 889–93PubMedCrossRefGoogle Scholar
  37. 37.
    Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database of Syst Rev 2007; (2): CD001269Google Scholar
  38. 38.
    Ahmed AH, Nicholson KG. The efficacy of influenza vaccine. Rev Med Microbiol 1996; 7 (1): 23–30CrossRefGoogle Scholar
  39. 39.
    Nichol KL. Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine 2001; 19 (31): 4373–7PubMedCrossRefGoogle Scholar
  40. 40.
    Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21 (17–18): 2207–17PubMedCrossRefGoogle Scholar
  41. 41.
    Olsen GW, Steinberg ME, Ley CA. Worksite influenza immunization programs: insight into the implementation and cost-benefit. AAOHN J 2005; 53 (3): 105–10PubMedGoogle Scholar
  42. 42.
    Szucs TD. Medical economics in the field of influenza: past, present and future. Virus Res 2004; 103 (1–2): 25–30PubMedCrossRefGoogle Scholar
  43. 43.
    Jefferson T, Demicheli V, Di Pietrantonj C, et al. Amantadine and rimantadine for influenza A in adults. Cochrane Database of Syst Rev 2006; (2): CD001169Google Scholar
  44. 44.
    Hayden FG, Atmar RL, Schilling M, et al. and the Oseltamivir Study Group. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43PubMedCrossRefGoogle Scholar
  45. 45.
    Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254–61PubMedCrossRefGoogle Scholar
  46. 46.
    Welliver R, Monto AS, Catewicz O, et al. for the Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54PubMedCrossRefGoogle Scholar
  47. 47.
    Hayden FG, Gubareva LV, Monto AS, et al. for the Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343: 1282–9PubMedCrossRefGoogle Scholar
  48. 48.
    Anonymous. Zanamivir and oseltamivirNew options in the management of influenza. Drugs Ther Persp 2000; 15 (6): 1–5CrossRefGoogle Scholar
  49. 49.
    McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med 2005; 4 (2): 107–16PubMedCrossRefGoogle Scholar
  50. 50.
    Schwarzinger M, Lacombe K, Carrat F. Economic evaluations of neuraminidase inhibitors to control influenza. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3 (2): 147–58CrossRefGoogle Scholar
  51. 51.
    Kumpulainen V, Mäkelä M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997; 29 (2): 181–5PubMedCrossRefGoogle Scholar
  52. 52.
    Carrat F, Sahler C, Rogez S, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Int Med 2002; 162 (16): 1842–8CrossRefGoogle Scholar
  53. 53.
    Aoki FY, Fleming DM, Griffin AD, et al. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Pharmacoeconomics 2000; 17 (2): 187–95PubMedCrossRefGoogle Scholar
  54. 54.
    Jacomo V, Sartor C, Zandotti C, et al. Nosocomial influenza outbreak in an intensive-care unit. Med Mal Infect 2001; 31 (9): 563–8CrossRefGoogle Scholar
  55. 55.
    Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect Control Hosp Epidemiol 2002; 23 (10): 615–9PubMedCrossRefGoogle Scholar
  56. 56.
    Ito Y, Sumi H, Kato T. Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test. J Infect Chemother 2006; 12 (2): 70–2PubMedCrossRefGoogle Scholar
  57. 57.
    Bosis S, Esposito S, Niesters HGM, et al. Impact of human metapneumovirus in childhood: comparison with respiratory syncytial virus and influenza viruses. J Med Virol 2005; 75: 101–4PubMedCrossRefGoogle Scholar
  58. 58.
    Esposito S, Gasparini R, Bosis S, et al. Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect 2005; 11 (11): 933–6PubMedCrossRefGoogle Scholar
  59. 59.
    Principi N, Esposito S, Gasparini R, et al. Burden of influenza in healthy children and their households. Arch Dis Child 2004; 89 (11): 1002–7PubMedCrossRefGoogle Scholar
  60. 60.
    Principi N, Esposito S, Marchisio P, et al. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003; 22 (10 Suppl.): S207–10Google Scholar
  61. 61.
    Carrat F, Schwarzinger M, Housset B, et al. Antibiotic treatment for influenza does not affect resolution of illness, secondary visits or lost workdays. Eur J Epidemiol 2004; 19 (7): 703–5PubMedCrossRefGoogle Scholar
  62. 62.
    Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults cost-effectiveness of rapid testing and antiviral therapy. J Gen Int Med 2003; 18 (10): 808–15CrossRefGoogle Scholar
  63. 63.
    Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118 (1): 68–77PubMedCrossRefGoogle Scholar
  64. 64.
    Das Gupta R, Guest JF. A model to estimate the cost benefit of an occupational vaccination programme for influenza with influvac in the UK. Pharmacoeconomics 2002; 20 (7): 475–84PubMedCrossRefGoogle Scholar
  65. 65.
    Millot JL, Aymard M, Bardol A. Reduced efficiency of influenza vaccine in prevention of influenza-like illness in working adults: a 7 month prospective survey in EDF Gaz de France employees, in Rhone-Alpes, 1996–1997. Occup Med 2002; 52 (5): 281–92CrossRefGoogle Scholar
  66. 66.
    Sessa A, Costa B, Bamfi F, et al. The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy. Fam Pract 2001; 18 (6): 629–34PubMedCrossRefGoogle Scholar
  67. 67.
    Gaillat J, Pecking M, El Sawi A, et al. Neuraminidase inhibitors in the general practice management of influenza: who prescribes them, when and with which results? Med Mal Infect 2005; 35 (9): 435–42PubMedCrossRefGoogle Scholar
  68. 68.
    Lambert S, O’Grady KA, Gabriel S, et al. The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use. Commun Dis Intell 2004; 28 (4): 510–6Google Scholar
  69. 69.
    Ng TP, Pwee KH, Niti M, et al. Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singap 2002; 31 (2): 182–8PubMedGoogle Scholar
  70. 70.
    Ramadan PA, de Araujo FB, Ferreira Jr M. A 12-month follow-up of an influenza vaccination campaign based on voluntary adherence: report on upper-respiratory symptoms among volunteers and non-volunteers. Rev Paul Med 2001; 119 (4): 142–5Google Scholar
  71. 71.
    Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284 (13): 1655–63PubMedCrossRefGoogle Scholar
  72. 72.
    Dille JH. A worksite influenza immunization program: impact on lost work days, health care utilization, and health care spending. AAOHN J 1999; 47 (7): 301–9PubMedGoogle Scholar
  73. 73.
    Mixeu MA, Vespa GN, Forleo-Neto E, et al. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviat Space Environ Med 2002; 73 (9): 876–80PubMedGoogle Scholar
  74. 74.
    King Jr JC, Cummings GE, Stoddard J, et al. A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics 2005; 116 (6): e868–73CrossRefGoogle Scholar
  75. 75.
    Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999; 18 (9): 779–83PubMedCrossRefGoogle Scholar
  76. 76.
    Akazawa M, Sindelar JL, Paltiel AD. Economic costs of influenza-related work absenteeism. Value Health 2003; 6 (2): 107–15PubMedCrossRefGoogle Scholar
  77. 77.
    Cohen P, Darling C, Hampson A, et al. Influenza vaccination in an occupational setting: effectiveness and cost-benefit study. J Occup Health Safe Aust NZ 2003; 19 (2): 167–82Google Scholar
  78. 78.
    Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002; 156 (10): 986–91PubMedGoogle Scholar
  79. 79.
    Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med 1998; 48 (2): 85–90CrossRefGoogle Scholar
  80. 80.
    Speroni KG, Dawson E, Atherton M, et al. Influenza vaccination: incidence of symptoms and resulting absenteeism in hospital employees. AAOHN J 2005; 53 (11): 477–83PubMedGoogle Scholar
  81. 81.
    Szucs TD, Ruef C, Muller D, et al. The economic impact of influenza in a university hospital setting. Infect Contr Hosp Epidemiol 2001; 22 (8): 472–4CrossRefGoogle Scholar
  82. 82.
    Jefferson T, Wegmuller Y, Barker C, et al. The impact of influenza on the workplace and the effect of the antiviral GS4104 on daily performance and work absenteeism [abstract]. J Antimicrob Chemother 1999; 44 Suppl. A: 46Google Scholar
  83. 83.
    Briner RB. ABC of work related disorders: absence from work. BMJ 1996; 313 (7061): 874–7PubMedCrossRefGoogle Scholar
  84. 84.
    Smith AP, Thomas M, Brockman P, et al. Effect of influenza B virus infection on human performance. BMJ 1993; 306: 760–1PubMedCrossRefGoogle Scholar
  85. 85.
    Postma MJ, Jansema P, van Genugten ML, et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002; 62 (7): 1013–24PubMedCrossRefGoogle Scholar
  86. 86.
    Watanabe A, Kobayashi M. Socioeconomic analysis of oseltamivir for influenza patients. Jpn J Chemother 2001; 49 (2): 95–102Google Scholar
  87. 87.
    Prosser LA, O’Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmaceoeconomics 2008; 26 (2): 163–78CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Pharmakos Ltd.St AlbansUK
  2. 2.F. Hoffmann-La Roche LtdBaselSwitzerland

Personalised recommendations